Role of antibiotics in tumor development and immunotherapy

Abstract

Abstract:

In recent years, immunotherapy with immune checkpoint inhibitor (ICI) as the representative drug has become an important treatment method for advanced malignant tumors. Preclinical studies have found that disorders of the gut microbiota can reduce the clinical benefit of patients treated with ICI. The latest data indicate that antibiotics may further affect the occurrence and development of tumors and the efficacy of immunotherapy by changing the abundance and composition of intestinal microbiota. To sum up the role of anti-biotics in the immunotherapy of advanced malignant tumor may provide a new idea for the optimization of treatment strategies for patients with advanced cancer.

Key words:Anti-bacterial agents,Immunotherapy,Microbiota,Prognosis

Yang Mengxue, Yuan Man, Tong Jiandong, Yan Xuebing. Role of antibiotics in tumor development and immunotherapy[J]. Journal of International Oncology, 2021, 48(1): 48-51.

References26

[1]	Hartmann FJ, Babdor J, Gherardini PF, et al. Comprehensive immune monitoring of clinical trials to advance human immunotherapy[J]. Cell Rep, 2019,28(3): 819-831.e4. DOI: 10.1016/j.celrep.2019.06.049.
[2]	Nie P, Li Z, Wang Y, et al. Gut microbiome interventions in human health and diseases[J]. Med Res Rev, 2019,39(6):2286-2313. DOI: 10.1002/med.21584. doi:10.1002/med.21584pmid:30994937
[3]	Wei MY, Shi S, Liang C, et al. The microbiota and microbiome in pancreatic cancer: more influential than expected[J]. Mol Cancer, 2019,18(1):97. DOI: 10.1186/s12943-019-1008-0. pmid:31109338
[4]	Baba Y, Iwatsuki M, Yoshida N, et al. Review of the gut microbiome and esophageal cancer: pathogenesis and potential clinical implications[J]. Ann Gastroenterol Surg, 2017,1(2):99-104. DOI: 10.1002/ags3.12014. pmid:29863142
[5]	Bullman S, Pedamallu CS, Sicinska E, et al. Analysis of fusobacte-rium persistence and antibiotic response in colorectal cancer[J]. Science, 2017,358(6369):1443-1448. DOI: 10.1126/science.aal5240. pmid:29170280
[6]	Wirbel J, Pyl PT, Kartal E, et al. Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer[J]. Nat Med, 2019,25(4):679-689. DOI: 10.1038/s41591-019-0406-6. doi:10.1038/s41591-019-0406-6pmid:30936547
[7]	Alexander JL, Wilson ID, Teare J, et al. Gut microbiota modulation of chemotherapy efficacy and toxicity[J]. Nat Rev Gastroenterol Hepatol, 2017,14(6):356-365. DOI: 10.1038/nrgastro.2017.20. doi:10.1038/nrgastro.2017.20pmid:28270698
[8]	Wang Y, Wiesnoski DH, Helmink BA, et al. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis[J]. Nat Med, 2018,24(12):1804-1808. DOI: 10.1038/s41591-018-0238-9. doi:10.1038/s41591-018-0238-9pmid:30420754
[9]	Rosa CP, Brancaglion GA, Miyauchi-Tavares TM, et al. Antibiotic-induced dysbiosis effects on the murine gastrointestinal tract and their systemic repercussions[J]. Life Sci, 2018,207:480-491. DOI: 10.1016/j.lfs.2018.06.030. doi:10.1016/j.lfs.2018.06.030pmid:30056862
[10]	Russell B, Garmo H, Beckmann K, et al. A case-control study of lower urinary-tract infections, associated antibiotics and the risk of developing prostate cancer using PCBaSe 3.0[J]. PLoS One, 2018,13(4):e0195690. DOI: 10.1371/journal.pone.0195690. doi:10.1371/journal.pone.0195690pmid:29649268
[11]	Zhang J, Haines C, Watson AJM, et al. Oral antibiotic use and risk of colorectal cancer in the United Kingdom, 1989-2012: a matched case-control study[J]. Gut, 2019,68(11):1971-1978. DOI: 10.1136/gutjnl-2019-318593. doi:10.1136/gutjnl-2019-318593pmid:31427405
[12]	Petrelli F, Ghidini M, Ghidini A, et al. Use of antibiotics and risk of cancer: a systematic review and meta-analysis of observational studies[J]. Cancers (Basel), 2019,11(8):1174. DOI: 10.3390/cancers11081174.
[13]	Sethi V, Kurtom S, Tarique M, et al. Gut microbiota promotes tumor growth in mice by modulating immune response[J]. Gastroenterology, 2018,155(1):33-37.e6. DOI: 10.1053/j.gastro.2018.04.001. pmid:29630898
[14]	Yan C, Tu XX, Wu W, et al. Antibiotics and immunotherapy in gastrointestinal tumors: friend or foe?[J]. World J Clin Cases, 2019,7(11):1253-1261. DOI: 10.12998/wjcc.v7.i11.1253. doi:10.12998/wjcc.v7.i11.1253pmid:31236389
[15]	Schoenfeld AJ, Hellmann MD. Acquired resistance to immune checkpoint inhibitors[J]. Cancer Cell, 2020,37(4):443-455. DOI: 10.1016/j.ccell.2020.03.017. doi:10.1016/j.ccell.2020.03.017pmid:32289269
[16]	Hermel DJ, Sigal D. The emerging role of checkpoint inhibition in microsatellite stable colorectal cancer[J]. J Pers Med, 2019,9(1):5. DOI: 10.3390/jpm9010005.
[17]	Eng C, Kim TW, Bendell J, et al. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial[J]. Lancet Oncol, 2019,20(6):849-861. DOI: 10.1016/S1470-2045(19)30027-0. doi:10.1016/S1470-2045(19)30027-0pmid:31003911
[18]	Aguiar PN Jr, De Mello RA, Hall P, et al. PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data[J]. Immunotherapy, 2017,9(6):499-506. DOI: 10.2217/imt-2016-0150. doi:10.2217/imt-2016-0150pmid:28472902
[19]	Derosa L, Hellmann MD, Spaziano M, et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer[J]. Ann Oncol, 2018,29(6):1437-1444. DOI: 10.1093/annonc/mdy103. pmid:29617710
[20]	Pinato DJ, Howlett S, Ottaviani D, et al. Association of prior anti-biotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer[J]. JAMA Oncol, 2019,5(12):1774-1778. DOI: 10.1001/jamaoncol.2019.2785. doi:10.1001/jamaoncol.2019.2785pmid:31513236
[21]	Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors[J]. Science, 2018,359(6371):91-97. DOI: 10.1126/science.aan3706. pmid:29097494
[22]	Kaderbhai C, Richard C, Fumet JD, et al. Antibiotic use does not appear to influence response to nivolumab[J]. Anticancer Res, 2017,37(6):3195-3200. DOI: 10.21873/anticanres.11680. doi:10.21873/anticanres.11680pmid:28551664
[23]	Tinsley N, Zhou C, Tan G, et al. Cumulative antibiotic use significantly decreases efficacy of checkpoint inhibitors in patients with advanced cancer[J]. Oncologist, 2020,25(1):55-63. DOI: 10.1634/theoncologist.2019-0160. doi:10.1634/theoncologist.2019-0160pmid:31292268
[24]	Ahmed J, Kumar A, Parikh K, et al. Use of broad-spectrum anti-biotics impacts outcome in patients treated with immune checkpoint inhibitors[J]. Oncoimmunology, 2018,7(11):e1507670. DOI: 10.1080/2162402X.2018.1507670. doi:10.1080/2162402X.2018.1507670pmid:30377571
[25]	Huang XZ, Gao P, Song YX, et al. Antibiotic use and the efficacy of immune checkpoint inhibitors in cancer patients: a pooled analysis of 2740 cancer patients[J]. Oncoimmunology, 2019,8(12):e1665973. DOI: 10.1080/2162402X.2019.1665973. doi:10.1080/2162402X.2019.1665973pmid:31741763
[26]	Suez J, Zmora N, Zilberman-Schapira G, et al. Post-antibiotic gut mucosal microbiome reconstitution is impaired by probiotics and improved by autologous FMT[J]. Cell, 2018,174(6):1406-1423.e16. DOI: 10.1016/j.cell.2018.08.047. pmid:30193113